Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Nike Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.59 (market cap $39.89B), while Nike Inc trades at $44.11 (market cap $65.71B). The key difference: Nike Inc is the larger of the two by market cap, and Nike Inc pays a 3.7% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NKE | |
|---|---|---|
Market Cap | $39.89B | $65.71B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $79.24 |
52-Week Low | $278.09 | $40.75 |
Enterprise Value | $38.15B | $67.71B |
Volume | — | 8,887,180 |
Dividend Yield | — | 3.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Nike (NKE) trades at $44.37, up 3.72% in the last session, with a bearish technical signal but recent earnings beats. The company shows strong profitability with a 42.91% gross margin and 22.14% ROE, though revenue declined to $46.31B in 2025. Analysts maintain a $50.80 consensus target with 48.57% buy ratings, while news highlights challenges in China and inventory management.
Nike's outlook is mixed: solid brand strength and margin control support upside, but near-term headwinds in key markets and volatile cash flows pose risks. The stock offers potential for recovery if turnaround strategies gain traction, yet investors face uncertainty from competitive pressures and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
